Trials / Recruiting
RecruitingNCT07105254
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Derm Texas, PLLC · Network
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast topical 0.3% foam | Roflumilast 0.3% topical foam |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2026-05-15
- Completion
- 2026-06-15
- First posted
- 2025-08-05
- Last updated
- 2025-08-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07105254. Inclusion in this directory is not an endorsement.